(NASDAQ: LUNG) Pulmonx's forecast annual revenue growth rate of 8.15% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.48%.
Pulmonx's revenue in 2026 is $87,442,000.On average, 7 Wall Street analysts forecast LUNG's revenue for 2026 to be $3,969,279,021, with the lowest LUNG revenue forecast at $3,788,037,326, and the highest LUNG revenue forecast at $4,117,235,808. On average, 7 Wall Street analysts forecast LUNG's revenue for 2027 to be $4,306,852,415, with the lowest LUNG revenue forecast at $3,977,439,192, and the highest LUNG revenue forecast at $4,613,503,056.
In 2028, LUNG is forecast to generate $4,774,559,065 in revenue, with the lowest revenue forecast at $4,263,646,457 and the highest revenue forecast at $5,140,907,799.